Jefferies maintains SFBC buy

SFBC International was maintained at buy with a $35 price target by Jefferies & Co. Inc. analyst David Windley after a second Bloomberg story accused SFBC of attempts to coerce false statements from clinical study participants. SFBC management vehemently denied these claims. Jefferies is concerned that that regulators may be "deployed to find something," but Windley said valuation is cheap enough that financial engineering, such as a Dutch tender or leveraged buyout, could drive attractive returns to shareholders. Shares of the Miami-based research services company were up 97 cents, or 3.74%, at $26.94 on volume of 2,932,945 shares versus the three-month running average of 571,313 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.